Gain Therapeutics Operating Income Over Time
| GANX Stock | USD 1.94 0.05 2.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Gain Therapeutics Performance and Gain Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gain Therapeutics. Market participants price Gain higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Gain Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Gain Therapeutics requires distinguishing between market price and book value, where the latter reflects Gain's accounting equity. The concept of intrinsic value - what Gain Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Gain Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Gain Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gain Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Gain Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Gain Therapeutics and related stocks such as CervoMed, Adagene, and XBiotech Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRVO | 613 K | (16.4 M) | (11.8 M) | (7.9 M) | (7.3 M) | (6.4 M) | (14.9 M) | (11.3 M) | (12 M) | (11.6 M) | (16 M) | (24.7 M) | (16 M) | (7.8 M) | (18.2 M) | (16.4 M) | (15.6 M) |
| ADAG | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (19.2 M) | (19.2 M) | (72.4 M) | (83.9 M) | (23.7 M) | (36 M) | (32.4 M) | (34 M) |
| XBIT | (15.2 M) | (15.2 M) | (15.2 M) | (9.9 M) | (21.8 M) | (37.5 M) | (52.8 M) | (34.1 M) | (21 M) | (31.2 M) | (18.3 M) | (25.1 M) | (34.5 M) | (37.5 M) | (42.5 M) | (38.2 M) | (40.1 M) |
| ACET | 21.4 M | 16.6 M | 25.4 M | 34.4 M | 34.4 M | 44.3 M | (1000) | (18.9 M) | (15 M) | (31.4 M) | (39.2 M) | (61.4 M) | (72.6 M) | (152 M) | (127.6 M) | (114.9 M) | (109.1 M) |
| NTRB | (400) | (400) | (400) | (400) | (400) | (400) | (151.3 K) | (171.9 K) | (3.3 M) | (2 M) | (2.6 M) | (3.9 M) | (4.1 M) | (4.9 M) | (6.7 M) | (6 M) | (5.7 M) |
| LITS | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (60.4 M) | (75.5 M) | (36.8 M) | 14.5 M | (17.5 M) | (20.1 M) | (21.1 M) |
| FBIO | (3.2 M) | (35 M) | (27.2 M) | (35.8 M) | (20.7 M) | (50.5 M) | (65.7 M) | (89.8 M) | (120 M) | (110.8 M) | (94.3 M) | (188.5 M) | (203.6 M) | (142.3 M) | (110.4 M) | (99.3 M) | (104.3 M) |
| OSTX | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (4.8 M) | (4.4 M) | (4.3 M) | (6.8 M) | (6.1 M) | (6.4 M) |
| NRXP | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (1 M) | (713.2 K) | (22.1 M) | (95.2 M) | (44.3 M) | (27.6 M) | (19.7 M) | (17.7 M) | (18.6 M) |
| TCRX | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (14.2 M) | (26.2 M) | (48.6 M) | (66.6 M) | (93.5 M) | (134.8 M) | (121.3 M) | (115.3 M) |
Gain Therapeutics and related stocks such as CervoMed, Adagene, and XBiotech Operating Income description
Operating Income is the amount of profit realized from Gain Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Gain Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Gain Therapeutics | GANX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 4800 Montgomery Lane, |
| Exchange | NASDAQ Exchange |
USD 1.94
Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.